Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
More News related to DNDN
- Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
- Dendreon (DNDN) January volatility at 58, May at 99 into meeting
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
More News related to Press Releases
- Cramer Tries His Best to Top-Tick Amazon (AMZN), Sets Street High $210 Price Target
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- JPMorgan (JPM) Could See $3B Revenues Hit On Derivatives Rules
- Goldman Issues 'Top Trades of 2010': Sees 2010, 2011 'Rather Strong Years', Gives Global, US, Euro, BRIC GDP Estimates
- More Thoughts On Apple's (AAPL) Quick Sell-Off Yesterday
SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following upcoming investor conferences.
Merriman Investor Summit 2009
New York City
Tuesday, November 10, 2009
11:00 a.m. ET
Credit Suisse 2009 Healthcare Conference
Phoenix, Arizona
Friday, November 13, 2009
11:30 a.m. ET
Lazard Capital Markets 6th Annual Healthcare Conference
New York City
Tuesday, November 17, 2009
10:55 a.m. ET
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
SOURCE Dendreon Corporation
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
